Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models

Rokeya Tasneen, Andrew Garcia, Paul J. Converse, Matthew D. Zimmerman, Veronique Dartois, Ekaterina Kurbatova, Andrew A. Vernon, Wendy Carr, Jason E. Stout, Kelly E. Dooley, Eric L. Nuermberger

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


A recent landmark trial showed a 4-month regimen of rifapentine, pyrazinamide, moxifloxacin, and isoniazid (PZMH) to be noninferior to the 6-month standard of care. Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen. In BALB/c mice, replacing rifapentine in the PZM backbone with bedaquiline (i.e., BZM) significantly reduced both lung CFU counts after 1 month and the proportion of mice relapsing within 3 months after completing 1.5 months of treatment. The addition of rifabutin to BZM (BZMRb) further increased the sterilizing activity. In the C3HeB/FeJ mouse model characterized by caseating lung lesions, treatment with BZMRb resulted in significantly fewer relapses than PZMH after 2 months of treatment. A regimen combining the new DprE1 inhibitor OPC-167832 and delamanid (BZOD) also had superior bactericidal and sterilizing activity compared to PZM in BALB/c mice and was similar in efficacy to PZMH in C3HeB/FeJ mice. Thus, BZM represents a promising backbone for treatment-shortening regimens. Given the prohibitive drug-drug interactions between bedaquiline and rifampin or rifapentine, the BZMRb regimen represents the best opportunity to combine, in one regimen, the treatment-shortening potential of the rifamycin class with that of BZM and deserves high priority for evaluation in clinical trials. Other 4-drug BZM-based regimens and BZOD represent promising opportunities for extending the spectrum of treatmentshortening regimens to rifamycin- and fluoroquinolone-resistant tuberculosis.

Original languageEnglish (US)
JournalAntimicrobial agents and chemotherapy
Issue number4
StatePublished - Apr 2022

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


  • OPC-167832
  • bedaquiline
  • delamanid
  • mouse model
  • moxifloxacin
  • pharmacokinetics
  • pyrazinamide
  • rifabutin
  • rifapentine
  • tuberculosis


Dive into the research topics of 'Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models'. Together they form a unique fingerprint.

Cite this